Implementation of H.R.5376 Inflation Reduction Act.
Issues related to the Medicaid Drug Rebate Program.
Education about the 340(b) program.
H.R.830 - HELP Copays Act.
H.R.5378 - Lower Costs, More Transparency Act.
S.2973 - Modernizing and Ensuring PBM Accountability Act.
Duration: July 1, 2010
to
present
General Issues: Medicare/Medicaid , Health Issues , Consumer Issues/Safety/Protection , Trade (Domestic & Foreign) , Taxation/Internal Revenue Code , Pharmacy , Defense , Budget/Appropriations , Copyright/Patent/Trademark , Veterans
Spending: about $3,300,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2010: House of Representatives, U.S. Senate, Office of the Vice President of the United States, Executive Office of the President (EOP), U.S. Senate,
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Darren Willcox Asst for Policy, Speaker Dennis Hastert
Admin Asst; Leg Dir; Leg Asst, Cong. Porter Goss
House Rules Comm Assoc, Subcomm Staff Dir.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, W Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on April 22.
Original Filing: 301575615.xml
Lobbying Issues
Implementation of H.R.5376 Inflation Reduction Act.
Issues related to the Medicaid Drug Rebate Program.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about the 340(b) program.
H.R.830 - HELP Copays Act.
H.R.5378 - Lower Costs, More Transparency Act.
S.2973 - Modernizing and Ensuring PBM Accountability Act.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2023
In Q4, W Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on Jan. 18.
Original Filing: 301529202.xml
Lobbying Issues
Implementation of H.R.5376 Inflation Reduction Act.
Issues related to the Medicaid Drug Rebate Program.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about the 340(b) program.
H.R.830 - HELP Copays Act.
H.R.5378 - Lower Costs, More Transparency Act.
S.2973 - Modernizing and Ensuring PBM Accountability Act.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2023
In Q3, W Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on Oct. 20, 2023.
Original Filing: 301511994.xml
Lobbying Issues
Implementation of H.R.5376 Inflation Reduction Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about the 340(b) program.
H.R.830 - HELP Copays Act.
H.R.5378 - Lower Costs, More Transparency Act.
H.R.3285 - Fairness for Patient Medications Act.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2023
In Q2, W Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on July 20, 2023.
Original Filing: 301489699.xml
Lobbying Issues
Implementation of H.R.5376 Inflation Reduction Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about the 340(b) program.
H.R.830 - HELP Copays Act.
Education about potential pharmacy benefit manager reforms.
H.R.3285 - Fairness for Patient Medications Act.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2023
In Q1, W Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on April 20, 2023.
Original Filing: 301463740.xml
Lobbying Issues
Implementation of H.R.5376 Inflation Reduction Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about the 340(b) program.
H.R.830 - HELP Copays Act.
Education about potential pharmacy benefit manager reforms.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2022
In Q4, W Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on Jan. 20, 2023.
Original Filing: 301436660.xml
Lobbying Issues
Implementation of H.R.5376 Inflation Reduction Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.4373 - Further Additional Continuing Appropriations and Extensions Act, 2023 as it relates to FDA policy riders.
Education about the 340(b) program.
H.R.5801 - HELP Copays Act.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2022
In Q3, W Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on Oct. 20, 2022.
Original Filing: 301419365.xml
Lobbying Issues
HR 5376 : Inflation Reduction Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S.4348 - FDASLA Act of 2022.
H.R.7667 - Food and Drug Amendments of 2022.
Education about the 340(B) program.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.8152 - American Data Privacy and Protection Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Consumer Issues/Safety/Protection
2nd Quarter, 2022
In Q2, W Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on July 20, 2022.
Original Filing: 301390424.xml
Lobbying Issues
H.R.5376: Build Back Better Act, including H.R.3: Elijah E. Cummings Lower Drug Costs Now Act and H.R.19. Lower Costs, More Cures Act of 2021.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.7667 - Food and Drug Amendments of 2022, S.4348 - FDASLA Act of 2022.
Education about the 340(B) program.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2022
In Q1, W Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on April 20, 2022.
Original Filing: 301369249.xml
Lobbying Issues
H.R.5376: Build Back Better Act, including H.R.3: Elijah E. Cummings Lower Drug Costs Now Act and H.R.19. Lower Costs, More Cures Act of 2021.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Reauthorization of the Prescription Drug User Fee Act and related issues.
Education about the 340(B) program.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2021
In Q4, W Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on Jan. 20, 2022.
Original Filing: 301331743.xml
Lobbying Issues
H.R.5376: Build Back Better Act, including H.R.3: Elijah E. Cummings Lower Drug Costs Now Act and H.R.19. Lower Costs, More Cures Act of 2021.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2021
In Q3, W Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on Oct. 20, 2021.
Original Filing: 301310218.xml
Lobbying Issues
FY'22 Budget Reconciliation including H.R.3: Elijah E. Cummings Lower Drug Costs Now Act. And H.R.19: Lower Costs, More Cures Act of 2021.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education around 340(b) program.
FY'22 Labor/HHS appropriations as it relates to the Preserving Rules Ordered for the Entities Covered Through (PROTECT) 340B Act.
Legislation around pediatric cancer clinical trials.
H.R.3684: Infrastructure Investment and Jobs Act as it relates to legislation around vial sizes.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2021
In Q2, W Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on July 20, 2021.
Original Filing: 301289978.xml
Lobbying Issues
H.R.3: Elijah E. Cummings Lower Drug Costs Now Act.
H.R.19: Lower Costs, More Cures Act of 2021.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education around 340(b) program.
H.R.2366: Support, Treatment, and Overdose Prevention of (STOP) Fentanyl Act of 2021.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to Covid-19 vaccines and TRIPS at WTO.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2021
In Q1, W Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on April 20, 2021.
Original Filing: 301266643.xml
Lobbying Issues
Administration final rule on international drug pricing.
Previous Congress H.R.107: "to sunset the limit on the maximum drug rebate amount for single source drugs.
CMS proposed demonstration on six protected classes.
H.R.1319: American Rescue Plan Act of 2021.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education around 340(b) program.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2020
In Q4, W Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on Jan. 20, 2021.
Original Filing: 301240699.xml
Lobbying Issues
Administration final rule on international drug pricing.
Administration rule related to safe harbors for certain drug rebates.
H.R.107: "to sunset the limit on the maximum drug rebate amount for single source drugs".
H.R.4996: Helping MOMS Act of 2020.
H.R.133: Consolidated Appropriations Act 2021, as it relates to health extenders.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education around the 340(b) program.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2020
In Q3, W Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on Oct. 20, 2020.
Original Filing: 301222704.xml
Lobbying Issues
FY 2021 Notice of Benefits and Payment Parameters Proposed Rule.
Executive Order on international drug pricing.
H.R.107: to sunset the limit on the maximum drug rebate amount for single source drugs.
H.R.4996: Helping MOMS Act of 2020.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to global pharmaceutical supply chains.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Tax incentives for domestic pharmaceutical manufacturing.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Education around the 340(b) program.
H.R.4439: Creating Hope Reauthorization Act.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2020
In Q2, W Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on July 20, 2020.
Original Filing: 301201723.xml
Lobbying Issues
FY 2021 Notice of Benefits and Payment Parameters Proposed Rule.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.4710: Pharmaceutical Independence Long-Term Readiness Reform Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
FY 2021 National Defense Authorization Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to global pharmaceutical supply chains.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Tax incentives for domestic pharmaceutical manufacturing.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2020
In Q1, W Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on April 20, 2020.
Original Filing: 301176872.xml
Lobbying Issues
H.R.107: To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.
Regulatory and legislative proposals in the Administrations Drug Pricing Blueprint.
H.R.3: Lower Drug Costs Now Act of 2019.
H.R.19: Lower Costs, More Cures Act of 2019.
S.2543: Prescription Drug Pricing Reduction Act of 2019.
FY 2021 Notice of Benefits and Payment Parameters Proposed Rule.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.4710 - Pharmaceutical Independence Long-Term Readiness Reform Act.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2019
In Q4, W Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on Jan. 21, 2020.
Original Filing: 301128932.xml
Lobbying Issues
H.R.107: To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.
Regulatory and legislative proposals in the Administrations Drug Pricing Blueprint.
H.R.3: Lower Drug Costs Now Act of 2019.
H.R.19: Lower Costs, More Cures Act of 2019.
S.2543: Prescription Drug Pricing Reduction Act of 2019.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
United States-Mexico-Canada Agreement (USMCA).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2019
In Q3, W Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on Oct. 21, 2019.
Original Filing: 301078500.xml
Lobbying Issues
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose efforts to impose mandatory government rebates in that program and concerns about beneficiary out of pocket costs.
H.R.107: To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.
Regulatory and legislative proposals in the Administrations Drug Pricing Blueprint.
CMS rule dealing with Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals.
H.R.3: Lower Drug Costs Now Act of 2019.
S.2543: Prescription Drug Pricing Reduction Act of 2019.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2019
In Q2, W Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on July 22, 2019.
Original Filing: 301056853.xml
Lobbying Issues
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose efforts to impose mandatory government rebates in that program and concerns about beneficiary out of pocket costs.
H.R.107: To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.
H.R.2113: Prescription Drug STAR Act.
H.R.2069: SPIKE Act.
H.R.2296: FAIR Drug Pricing Act of 2019.
Regulatory and legislative proposals in the Administrations Drug Pricing Blueprint.
CMS rule dealing with Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2019
In Q1, W Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on April 22, 2019.
Original Filing: 301035218.xml
Lobbying Issues
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose efforts to impose mandatory government rebates in that program and concerns about beneficiary out of pocket costs.
H.R. 107: To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.
Regulatory and legislative proposals in the Administrations Drug Pricing Blueprint
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2018
In Q4, W Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on Jan. 22, 2019.
Original Filing: 301015990.xml
Lobbying Issues
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose efforts to impose mandatory government rebates in that program and concerns about beneficiary out of pocket costs.
H.R.1892: Bipartisan Budget Act 2018 as it relates to a Part D donut hole provision.
H.R.7217: ACE Kids Act.
H.R.6642: To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about the 340(b) drug discount program.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2018
In Q3, W Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on Oct. 22, 2018.
Original Filing: 300994797.xml
Lobbying Issues
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose efforts to impose mandatory government rebates in that program and concerns about beneficiary out of pocket costs.
H.R.1892: Bipartisan Budget Act 2018 as it relates to a Part D donut hole provision.
H.R.6642: To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about the 340(b) drug discount program.
H.R.6: The Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2018
In Q2, W Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on July 20, 2018.
Original Filing: 300975780.xml
Lobbying Issues
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose efforts to impose mandatory government rebates in that program and concerns about beneficiary out of pocket costs.
H.R.1892: Bipartisan Budget Act of 2018 as it relates to a Part D "donut hole" provision.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about the 340(b) drug discount program.
H.R.6: the Substance Use-Disorder Prevention that Promotes Opioid Recover and Treatment (SUPPORT) for Patients and Communities Act.
H.R.5867: Reducing Drug Waste Act of 2018.
H.R.5228: SCREEN Act.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2018
In Q1, W Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on April 20, 2018.
Original Filing: 300956956.xml
Lobbying Issues
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose efforts to impose mandatory government rebates in that program and concerns about beneficiary out of pocket costs.
H.R.849: IPAB Repeal Act/H.J.Res 51: Joint Resolution related to IPAB Repeal.
CMS MA/Part D rule as it relates to rebates for beneficiaries.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about the 340(b) drug discount program.
Education about the value of innovative new medicines.
H.R. 195, as it relates to the HEALTHY KIDS Act CHIP reauthorization.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.1892: Bipartisan Budget Act of 2018 as it relates to a Part D coverage gap provision and IPAB repeal.
H.R.1625: Consolidated Appropriations Act, 2018.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2017
In Q4, W Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on Jan. 22, 2018.
Original Filing: 300933421.xml
Lobbying Issues
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose efforts to impose mandatory government rebates in that program and concerns about beneficiary out of pocket costs.
H.R.849: IPAB Repeal Act/H.J.Res 51: Joint Resolution related to IPAB Repeal.
Implementation of Medicare Access and Chip Reauthorization Act (MACRA).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about the 340(b) drug discount program.
Education about the value of innovative new medicines.
H.R.3922: CHAMPIONING HEALTHY KIDS Act.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2017
In Q3, W Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on Oct. 20, 2017.
Original Filing: 300915581.xml
Lobbying Issues
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose efforts to impose mandatory government rebates in that program and concerns about beneficiary out of pocket costs.
H.R. 849: IPAB Repeal Act/H.J.Res 51: Joint Resolution related to IPAB Repeal.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about the 340(b) drug discount program.
Education about the value of innovative new medicines.
H.R.1628: American Health Care Act and Better Care Reconciliation Act.
H.R.2430/S.934: FDA Reauthorization Act of 2017.
Reauthorization of the State Childrens Health Insurance Program.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
FY 2019 National Defense Authorization Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 3354 as it relates to the amendment offered by Rep. Carter (GA) relating to compounding pharmacies.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2017
In Q2, W Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on July 20, 2017.
Original Filing: 300897356.xml
Lobbying Issues
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose efforts to impose mandatory government rebates in that program and proposed changes to cost sharing for low income seniors and changes to laws affecting importation of prescription drugs from other countries.
H.R. 849: IPAB Repeal Act/H.J.Res 51: Joint Resolution related to IPAB Repeal.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about the 340(b) drug discount program.
Education about the value of innovative new medicines.
H.R. 1628: American Health Care Act.
H.R.2430/S.934: FDA Reauthorization Act of 2017.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2017
In Q1, W Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on April 21, 2017.
Original Filing: 300878603.xml
Lobbying Issues
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose efforts to impose mandatory government rebates in that program and proposed changes to cost sharing for low income seniors.
H.R. 849: IPAB Repeal Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about the 340(b) drug discount program.
Education about the value of innovative new medicines.
H.R. 749: Lower Drugs Through More Competition Act.
H.R. 1628: American Health Care Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
FY 2017 Budget Resolution.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2016
In Q4, W Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on Jan. 23, 2017.
Original Filing: 300855353.xml
Lobbying Issues
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose efforts to impose mandatory government rebates in that program and proposed changes to cost sharing for low income seniors.
March 2016 CMS proposed rule implementing a new Part B drug payment model.
H.R.5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about the 340(b) drug discount program.
H.R. 34: 21st Century Cures Act Conference Report.
Education about the value of innovative new medicines.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2016
In Q3, W Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on Oct. 20, 2016.
Original Filing: 300835143.xml
Lobbying Issues
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose efforts to impose mandatory government rebates in that program and proposed changes to cost sharing for low income seniors.
March 2016 CMS proposed rule implementing a new Part B drug payment model.
H.R.5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about the 340(b) drug discount program.
H.R. 6174: Closing Loopholes for Orphan Drugs Act.
H.R. 6: 21st Century Cures Act.
Education about the value of innovative new medicines.
S.524: Comprehensive Addiction and Recovery Act of 2016.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2016
In Q2, W Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on July 20, 2016.
Original Filing: 300821723.xml
Lobbying Issues
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose efforts to impose mandatory government rebates in that program and proposed changes to cost sharing for low income seniors.
March 2016 CMS proposed rule implementing a new Part B drug payment model.
H.R.5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about the 340(b) drug discount program.
H.R. 6: 21st Century Cures Act.
Education about the value of innovative new medicines.
S.524: Comprehensive Addiction and Recovery Act of 2016 as it relates to Rx take back programs.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2016
In Q1, W Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on April 20, 2016.
Original Filing: 300803077.xml
Lobbying Issues
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose efforts to impose mandatory government rebates in that program and proposed changes to cost sharing for low income seniors.
March 2016 CMS proposed rule implementing a new Part B drug payment model.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about the 340(b) drug discount program.
H.R. 6: 21st Century Cures Act.
H.R.3513: Prescription Drug Affordability Act of 2015.
Education about the value of innovative new medicines.
S.524: Comprehensive Addiction and Recovery Act of 2016 as it relates to Rx take back programs.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2015
In Q4, W Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on Jan. 19, 2016.
Original Filing: 300776334.xml
Lobbying Issues
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose efforts to impose mandatory government rebates in that program and proposed changes to cost sharing for low income seniors.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 3762: Restoring Americans Healthcare Freedom Reconciliation Act of 2015, including Senate amendments related to drug importation, data exclusivity for biologics, and Medicare drug rebates.
P.L. 114-113: "Consolidated Appropriations Act" with respect to the Protecting Americans from Tax Hikes Act and HHS study on prescription drug pricing.
Education about the 340(b) drug discount program.
H.R. 3537: Synthetic Drug Control Act of 2015.
H.R. 6: 21st Century Cures Act.
H.R. 2841: Fair Access for Safe and Timely Generics Act.
James Zadroga 9/11 Health and Compensation Reauthorization.
H.R. 3513: Prescription Drug Affordability Act of 2015.
Education about the value of innovative new medicines.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 9: Innovation Act, including changes to the Inter Partes Review process at PTO.
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2015
In Q3, W Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on Oct. 20, 2015.
Original Filing: 300763675.xml
Lobbying Issues
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose efforts to impose mandatory government rebates in that program and proposed changes to cost sharing for low income seniors.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about the 340(b) drug discount program.
H.R. 6: 21st Century Cures Act including: incentives for development of new medicines; proposed legislative changes to the 340(b) program; expanded access to medications and communications with health care professionals; proposed changes to biosimilars reimbursement and the Brat floor amendment related to NIH funding.
H.R. 2841: Fair Access for Safe and Timely Generics Act.
Education about the value of innovative new medicines.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 9: Innovation Act, including changes to the Inter Partes Review process at PTO.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2015
In Q2, W Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on July 20, 2015.
Original Filing: 300743524.xml
Lobbying Issues
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose efforts to impose mandatory government rebates in that program and proposed changes to cost sharing for low income seniors.
H.R. 2570: Strengthening Medicare Advantage Through Innovation and Transparency for Seniors.
H.R. 1190: Protecting Seniors Access to Medicare Act.
H.R. 2581: Preservation of Access for Seniors in Medicare Advantage Act of 2015.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about the 340(b) drug discount program.
H.R. 6: 21st Century Cures Act including: incentives for development of new medicines; proposed legislative changes to the 340(b) program; and expanded access to medications and communications with health care professionals.
H.R. 2841: Fair Access for Safe and Timely Generics Act.
Education about the value of innovative new medicines.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 9: Innovation Act, including changes to the Inter Partes Review process at PTO.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Trade Promotion Authority and Trade Adjustment Assistance legislation.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2015
In Q1, W Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on April 17, 2015.
Original Filing: 300718840.xml
Lobbying Issues
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose efforts to impose mandatory government rebates in that program and proposed changes to cost sharing for low income seniors.
H.R. 2: Medicare Access and CHIP Reauthorization Act of 2015.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
FY 2016 House and Senate Budget Resolutions, including proposed amendments to the Part D prescription drug program.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about the 340(b) drug discount program.
Legislative efforts to help accelerate the discovery, development and delivery of promising new treatments to patients (21st Century Cures).
Education about the value of innovative new medicines.
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2014
In Q4, W Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on Jan. 20, 2015.
Original Filing: 300704104.xml
Lobbying Issues
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose legislative efforts to impose mandatory government rebates in that program.
H.R. 5780: Protecting the Integrity of Medicare Act of 2014.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about the 340(b) drug discount program.
Legislative efforts to help accelerate the discovery, development and delivery of promising new treatments to patients (21st Century Cures).
Education about the value of innovative new medicines.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 5771: Tax Increase Prevention Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2014
In Q3, W Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on Oct. 20, 2014.
Original Filing: 300684866.xml
Lobbying Issues
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose legislative efforts to impose mandatory government rebates in that program.
H.R. 2995: Strengthening Medicare Anti-Fraud Measures Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about the 340(b) drug discount program.
Legislative efforts to help accelerate the discovery, development and delivery of promising new treatments to patients (21st Century Cures).
Education about the value of innovative new medicines.Implementation of Affordable Care Act as it relates to a regulatory pathway for biosimilars.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 4810: Veteran Access to Care Act of 2014.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2014
In Q2, W Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on July 14, 2014.
Original Filing: 300664730.xml
Lobbying Issues
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose legislative efforts to impose mandatory government rebates in that program.
H.R. 2995: Strengthening Medicare Anti-Fraud Measures Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about the 340(b) drug discount program.
FY 2015 Agriculture Appropriations bill, as it relates to amendments regarding regulation of drug label changes.
Legislative efforts to help accelerate the discovery, development and delivery of promising new treatments to patients (21st Century Cures).Education about the value of innovative new medicines.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 1720: Patent Transparency and Improvements Act.
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
H.R. 4810: Veteran Access to Care Act of 2014.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2014
In Q1, W Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on April 15, 2014.
Original Filing: 300645485.xml
Lobbying Issues
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose legislative efforts to impose mandatory government rebates in that program.
H.R. 4302: Protecting Access to Medicare Act of 2014.
H.R. 4160: Keep the Promise to Seniors Act of 2014.CMS proposed rule affecting the Medicare Advantage and Medicare Prescription Drug Benefit (Part D) Programs, specifically as it relates to changes to the Part D programs, including coverage of therapeutic classes and non interference.
Educated staff about concerns with changes in the Part D prescription drug program, specifically as it relates to changes in cost sharing for low income beneficiaries.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about the 340(b) drug discount program.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 1720: Patent Transparency and Improvements Act.
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2013
In Q4, W Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on Jan. 14, 2014.
Original Filing: 300621928.xml
Lobbying Issues
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose legislative efforts to impose mandatory government rebates in that program.
H.R. 351: Legislation to repeal the Independent Payment Advisory Board (IPAB).
H.R. 2810, S: Medicare Patient Access and Quality Improvement Act of 2013.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 2725: Food and Drug Administration Safety Over Sequestration Act of 2013.
Education about the 340(b) drug discount program.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.J. Res. 59 The Bipartisan Budget Act of 2013 Public Law No: 113-067.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 3309: Innovation Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2013
In Q3, W Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on Oct. 18, 2013.
Original Filing: 300607598.xml
Lobbying Issues
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose legislative efforts to impose mandatory government rebates in that program.
H.R. 351: Legislation to repeal the Independent Payment Advisory Board (IPAB).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 1919: Safeguarding Americas Pharmaceuticals Act of 2013.
S. 957: Drug Supply Chain Security Act.
S. 959: Pharmaceutical Compounding Quality and Accountability Act.
H.R. 3089: Compounding Clarity Act of 2013.H.R. 3024: The Drug Quality and Security Act.
H.R. 2725: Food and Drug Administration Safety Over Sequestration Act of 2013.
Education about the 340(b) drug discount program.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2013
In Q2, W Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on July 19, 2013.
Original Filing: 300577244.xml
Lobbying Issues
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose legislative efforts to impose mandatory government rebates in that program.
H.R. 351: Legislation to repeal the Independent Payment Advisory Board (IPAB).
Monitored legislative efforts to reform the Sustainable Growth Rate (SGR) formula for physicians in Medicare.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Federal legislative efforts to enhance the security and integrity of the domestic pharmaceutical distribution system.
Legislative proposals to enable provisional FDA approval of certain drugs.
Monitored legislative efforts to regulate compounding pharmacies.
H.R. 1919: Safeguarding Americas Pharmaceuticals Act of 2013.S. 957: Drug Supply Chain Security Act.
S. 959: Pharmaceutical Compounding Quality and Accountability Act.
H.R. 2410 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act as it relates to sequestration of drug and device user fees.
H.R. 2090: Patient Choice Act of 2013.
Education about the 340(b) drug discount program.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2013
In Q1, W Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on April 21, 2013.
Original Filing: 300558918.xml
Lobbying Issues
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose legislative efforts to impose mandatory government rebates in that program.
H.R. 8: American Taxpayer Relief Act of 2012 as it relates to sequestration and Medicare, including updates to the Medicare Sustainable Growth rate formula for physicians and related issues.H.R. 351: Legislation to repeal the Independent Payment Advisory Board (IPAB).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Federal legislative efforts to enhance the security and integrity of the domestic pharmaceutical distribution system.
Legislative proposals to enable provisional FDA approval of certain drugs.
Monitored legislative efforts to regulate compounding pharmacies.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. Con. Res. 8: Vitter amendment to ban drug patent settlements.
4th Quarter, 2012
In Q4, W Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on Jan. 14, 2013.
Original Filing: 300536662.xml
Lobbying Issues
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose efforts to impose mandatory government rebates in that program.
H.R. 8: American Taxpayer Relief Act of 2012 as it relates to sequestration and Medicare, including updates to the Medicare Sustainable Growth rate formula for physicians and related issues.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Advocated for establishing a uniform national approach to electronic tracking of prescription drugs for supply chain security.
H.R. 1513 and S.810: Great Ape Protection and Cost Savings Act of 2011.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2012
In Q3, W Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on Oct. 10, 2012.
Original Filing: 300512165.xml
Lobbying Issues
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose efforts to impose mandatory government rebates in that program.
Educated staff about issues related to closing the coverage gap in the Medicare Part D prescription drug benefit.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Advocated for establishing a uniform national approach to electronic tracking of prescription drugs for supply chain security.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2012
In Q2, W Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on July 19, 2012.
Original Filing: 300494176.xml
Lobbying Issues
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose efforts to impose mandatory government rebates in that program.
Educated staff about issues related to closing the coverage gap in the Medicare Part D prescription drug benefit.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 5651: Food and Drug Administration Reform Act of 2012, S. 3187: Food and Drug Administration Safety and Innovation Act of 2012, provisions relating to drugs and biologics, including drug shortages and incentives for pediatric drug development.
Advocated for establishing a uniform national approach to electronic tracking of prescription drugs for supply chain security.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2012
In Q1, W Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on April 4, 2012.
Original Filing: 300464052.xml
Lobbying Issues
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose efforts to impose mandatory government rebates in that program.
H.R. 5: Help Efficient, Accessible, Low-cost, Timely Healthcare Act.
H.R. 452: Medicare Decisions Accountability Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education regarding the Prescription Drug User Fee Act Reauthorization for FY 2013-2017.
Education about legislative proposals to address prescription drug shortages.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H. Con. Res. 112: FY 2013 Budget Resolution.
Education regarding the importance of maintaining current law as it relates to biosimilars and opposing efforts in the President's Budget to shorten the term of data exclusivity for innovator biologics.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2011
In Q4, W Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on Jan. 19, 2012.
Original Filing: 300445657.xml
Lobbying Issues
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose efforts to impose mandatory government rebates in that program.
P.L. 112-25 - The Budget Control Act of 2011 as it relates to proposals to impose mandatory rebates in the Part D program.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education regarding the upcoming Prescription Drug User Fee Act Reauthorization for FY 2013-2017.
Education about legislative proposals to address prescription drug shortages.
S. 27: Preserve Access to Affordable Generics Act.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2011
In Q3, W Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on Oct. 20, 2011.
Original Filing: 300424153.xml
Lobbying Issues
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose efforts to impose mandatory government rebates in that program.
Education about the negative consequences for Medicare beneficiaries and the health care system if the Independent Payment Advisory Board is not repealed.Monitored deficit reduction initiatives related to enactment of an increase in the U.S. federal debt ceiling.
P.L. 112-25 - The Budget Control Act of 2011 as it relates to proposals to impose mandatory rebates in the Part D program.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education regarding the Prescription Drug User Fee Act.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2011
In Q2, W Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on July 17, 2011.
Original Filing: 300391900.xml
Lobbying Issues
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose efforts to impose mandatory government rebates in that program.
Education about the negative consequences for Medicare beneficiaries and the health care system if the Independent Payment Advisory Board is not repealed.Monitored deficit reduction initiatives related to enactment of an increase in the U.S. federal debt ceiling.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Patent Reform.
S. 23 - America Invents Act of 2011.
H.R. 1249 - America Invents Act of 2011.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2011
In Q1, W Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on April 13, 2011.
Original Filing: 300370102.xml
Lobbying Issues
Monitoring the implementation of the Patient Protection and Affordable Care Act, including provisions related to comparative effectiveness research and a regulatory pathway for biosimilars.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Monitoring the implementation of the Patient Protection and Affordable Care Act, including provisions related to comparative effectiveness research.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Patent Reform.
S. 23 - America Invents Act of 2011
H.R. 1249 - America Invents Act of 2011
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2010
In Q4, W Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on Jan. 12, 2011.
Original Filing: 300346631.xml
Lobbying Issues
Monitoring the implementation of the Patient Protection and Affordable Care Act, including provisions related to comparative effectiveness research and a regulatory pathway for biosimilars.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Monitoring the implementation of the Patient Protection and Affordable Care Act, including provisions related to comparative effectiveness research.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2010
In Q3, W Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on Oct. 15, 2010.
Original Filing: 300321358.xml
Lobbying Issues
Monitoring the implementation of the Patient Protection and Affordable Care Act, including provisions related to comparative effectiveness research and a regulatory pathway for biosimilars.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Monitoring the implementation of the Patient Protection and Affordable Care Act, including provisions related to comparative effectiveness research.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2010
W Strategies, LLC filed a lobbying registration on Aug. 9, 2010 to represent Pharmaceutical Research and Manufacturers of America, effective July 1, 2010.
Original Filing: 300306738.xml
Issue(s) they said they’d lobby about: Implementation of PPACA, including provisions related to comparative effectiveness research and a regulatory pathway for biosimilars.
Patent and Trademark Office Fee Modernization.
American Jobs and Closing Tax Loopholes. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...